0001626199-24-000066.txt : 20240509 0001626199-24-000066.hdr.sgml : 20240509 20240509211307 ACCESSION NUMBER: 0001626199-24-000066 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240507 FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rickey James Paul CENTRAL INDEX KEY: 0001606243 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37449 FILM NUMBER: 24932623 MAIL ADDRESS: STREET 1: ALPINE IMMUNE SCIENCES, INC. STREET 2: 188 EAST BLAINE STREET, SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC. CENTRAL INDEX KEY: 0001626199 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 208969493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-788-4545 MAIL ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Nivalis Therapeutics, Inc. DATE OF NAME CHANGE: 20150211 FORMER COMPANY: FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141121 4 1 wk-form4_1715303576.xml FORM 4 X0508 4 2024-05-07 0 0001626199 ALPINE IMMUNE SCIENCES, INC. ALPN 0001606243 Rickey James Paul C/O ALPINE IMMUNE SCIENCES, INC. 188 EAST BLAINE STREET, SUITE 200 SEATTLE WA 98102 0 1 0 0 See Remarks 0 Common Stock 2024-05-07 4 M 0 1 7.55 A 31201 D Common Stock 2024-05-07 4 M 0 7055 13.20 A 38256 D Common Stock 2024-05-07 4 M 0 857 6.51 A 39113 D Common Stock 2024-05-07 4 M 0 164 11.31 A 39277 D Common Stock 2024-05-07 4 M 0 18286 3.23 A 57563 D Common Stock 2024-05-07 4 M 0 398 5.02 A 57961 D Stock Option (Right to buy) 7.55 2024-05-07 4 M 0 1 0 D 2033-01-03 Common Stock 1 108999 D Stock Option (Right to buy) 13.20 2024-05-07 4 M 0 7055 0 D 2031-01-04 Common Stock 7055 112945 D Stock Option (Right to buy) 6.51 2024-05-07 4 M 0 857 0 D 2029-02-05 Common Stock 857 143 D Stock Option (Right to buy) 11.31 2024-05-07 4 M 0 164 0 D 2028-01-01 Common Stock 164 836 D Stock Option (Right to buy) 3.23 2024-05-07 4 M 0 18286 0 D 2030-01-22 Common Stock 18286 1214 D Stock Option (Right to buy) 5.02 2024-05-07 4 M 0 398 0 D 2027-04-11 Common Stock 398 137 D Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024. The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date. Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 5, 2021 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date. 100% of the shares underlying the option were fully vested as of February 6, 2023. 100% of the shares underlying the option were fully vested as of January 2, 2022. 100% of the shares underlying the option were fully vested as of January 23, 2024. 100% of shares underlying the option were fully vested as of April 1, 2021. Senior Vice President, Chief Financial Officer and Corporate Secretary /s/ James Paul Rickey 2024-05-09